table of content
1 Study Coverage
1.1 Urological Cancer Drugs Product Introduction
1.2 Global Urological Cancer Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Urological Cancer Drugs Sales in US$ Million for the Year 2017-2028
1.2.2 Global Urological Cancer Drugs Sales in Volume for the Year 2017-2028
1.3 United States Urological Cancer Drugs Outlook 2017 VS 2022 VS 2028
1.3.1 United States Urological Cancer Drugs Sales in US$ Million for the Year 2017-2028
1.3.2 United States Urological Cancer Drugs Sales in Volume for the Year 2017-2028
1.4 Urological Cancer Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Urological Cancer Drugs in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Urological Cancer Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Urological Cancer Drugs Market Dynamics
1.5.1 Urological Cancer Drugs Industry Trends
1.5.2 Urological Cancer Drugs Market Drivers
1.5.3 Urological Cancer Drugs Market Challenges
1.5.4 Urological Cancer Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Urological Cancer Drugs Market Segment by Type
2.1.1 Tablets
2.1.2 Injection
2.2 Global Urological Cancer Drugs Market Size by Type
2.2.1 Global Urological Cancer Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Urological Cancer Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Urological Cancer Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Urological Cancer Drugs Market Size by Type
2.3.1 United States Urological Cancer Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Urological Cancer Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Urological Cancer Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Urological Cancer Drugs Market Segment by Application
3.1.1 Prostate Cancer
3.1.2 Bladder Cancer
3.1.3 Kidney Cancer
3.1.4 Testicular Cancer
3.1.5 Others
3.2 Global Urological Cancer Drugs Market Size by Application
3.2.1 Global Urological Cancer Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Urological Cancer Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Urological Cancer Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Urological Cancer Drugs Market Size by Application
3.3.1 United States Urological Cancer Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Urological Cancer Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Urological Cancer Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Urological Cancer Drugs Competitor Landscape by Company
4.1 Global Urological Cancer Drugs Market Size by Company
4.1.1 Top Global Urological Cancer Drugs Manufacturers Ranked by Revenue (2021)
4.1.2 Global Urological Cancer Drugs Revenue by Manufacturer (2017-2022)
4.1.3 Global Urological Cancer Drugs Sales by Manufacturer (2017-2022)
4.1.4 Global Urological Cancer Drugs Price by Manufacturer (2017-2022)
4.2 Global Urological Cancer Drugs Concentration Ratio (CR)
4.2.1 Urological Cancer Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Urological Cancer Drugs in 2021
4.2.3 Global Urological Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Urological Cancer Drugs Manufacturing Base Distribution, Product Type
4.3.1 Global Urological Cancer Drugs Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Urological Cancer Drugs Product Type
4.3.3 Date of International Manufacturers Enter into Urological Cancer Drugs Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Urological Cancer Drugs Market Size by Company
4.5.1 Top Urological Cancer Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Urological Cancer Drugs Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Urological Cancer Drugs Sales by Players (2020, 2021 & 2022)
5 Global Urological Cancer Drugs Market Size by Region
5.1 Global Urological Cancer Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Urological Cancer Drugs Market Size in Volume by Region (2017-2028)
5.2.1 Global Urological Cancer Drugs Sales in Volume by Region: 2017-2022
5.2.2 Global Urological Cancer Drugs Sales in Volume Forecast by Region (2023-2028)
5.3 Global Urological Cancer Drugs Market Size in Value by Region (2017-2028)
5.3.1 Global Urological Cancer Drugs Sales in Value by Region: 2017-2022
5.3.2 Global Urological Cancer Drugs Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Urological Cancer Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Urological Cancer Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Urological Cancer Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Urological Cancer Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Urological Cancer Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Urological Cancer Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Urological Cancer Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Urological Cancer Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Urological Cancer Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Urological Cancer Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Novartis
7.1.1 Novartis Corporation Information
7.1.2 Novartis Description and Business Overview
7.1.3 Novartis Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Novartis Urological Cancer Drugs Products Offered
7.1.5 Novartis Recent Development
7.2 Pfizer
7.2.1 Pfizer Corporation Information
7.2.2 Pfizer Description and Business Overview
7.2.3 Pfizer Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Pfizer Urological Cancer Drugs Products Offered
7.2.5 Pfizer Recent Development
7.3 Johnson & Johnson
7.3.1 Johnson & Johnson Corporation Information
7.3.2 Johnson & Johnson Description and Business Overview
7.3.3 Johnson & Johnson Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Johnson & Johnson Urological Cancer Drugs Products Offered
7.3.5 Johnson & Johnson Recent Development
7.4 AstraZeneca
7.4.1 AstraZeneca Corporation Information
7.4.2 AstraZeneca Description and Business Overview
7.4.3 AstraZeneca Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 AstraZeneca Urological Cancer Drugs Products Offered
7.4.5 AstraZeneca Recent Development
7.5 Astellas
7.5.1 Astellas Corporation Information
7.5.2 Astellas Description and Business Overview
7.5.3 Astellas Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Astellas Urological Cancer Drugs Products Offered
7.5.5 Astellas Recent Development
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Corporation Information
7.6.2 Bristol-Myers Squibb Description and Business Overview
7.6.3 Bristol-Myers Squibb Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Bristol-Myers Squibb Urological Cancer Drugs Products Offered
7.6.5 Bristol-Myers Squibb Recent Development
7.7 Abbott Laboratories
7.7.1 Abbott Laboratories Corporation Information
7.7.2 Abbott Laboratories Description and Business Overview
7.7.3 Abbott Laboratories Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Abbott Laboratories Urological Cancer Drugs Products Offered
7.7.5 Abbott Laboratories Recent Development
7.8 Celgene Corporation
7.8.1 Celgene Corporation Corporation Information
7.8.2 Celgene Corporation Description and Business Overview
7.8.3 Celgene Corporation Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Celgene Corporation Urological Cancer Drugs Products Offered
7.8.5 Celgene Corporation Recent Development
7.9 Dendreon Corporation
7.9.1 Dendreon Corporation Corporation Information
7.9.2 Dendreon Corporation Description and Business Overview
7.9.3 Dendreon Corporation Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Dendreon Corporation Urological Cancer Drugs Products Offered
7.9.5 Dendreon Corporation Recent Development
7.10 Ferring Pharmaceuticals
7.10.1 Ferring Pharmaceuticals Corporation Information
7.10.2 Ferring Pharmaceuticals Description and Business Overview
7.10.3 Ferring Pharmaceuticals Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Ferring Pharmaceuticals Urological Cancer Drugs Products Offered
7.10.5 Ferring Pharmaceuticals Recent Development
7.11 GlaxoSmithKline
7.11.1 GlaxoSmithKline Corporation Information
7.11.2 GlaxoSmithKline Description and Business Overview
7.11.3 GlaxoSmithKline Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
7.11.4 GlaxoSmithKline Urological Cancer Drugs Products Offered
7.11.5 GlaxoSmithKline Recent Development
7.12 Indevus Pharmaceuticals Inc
7.12.1 Indevus Pharmaceuticals Inc Corporation Information
7.12.2 Indevus Pharmaceuticals Inc Description and Business Overview
7.12.3 Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Indevus Pharmaceuticals Inc Products Offered
7.12.5 Indevus Pharmaceuticals Inc Recent Development
7.13 Ipsen
7.13.1 Ipsen Corporation Information
7.13.2 Ipsen Description and Business Overview
7.13.3 Ipsen Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Ipsen Products Offered
7.13.5 Ipsen Recent Development
7.14 Roche Healthcare
7.14.1 Roche Healthcare Corporation Information
7.14.2 Roche Healthcare Description and Business Overview
7.14.3 Roche Healthcare Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Roche Healthcare Products Offered
7.14.5 Roche Healthcare Recent Development
7.15 Sanofi S.A
7.15.1 Sanofi S.A Corporation Information
7.15.2 Sanofi S.A Description and Business Overview
7.15.3 Sanofi S.A Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Sanofi S.A Products Offered
7.15.5 Sanofi S.A Recent Development
7.16 Tolmar Inc
7.16.1 Tolmar Inc Corporation Information
7.16.2 Tolmar Inc Description and Business Overview
7.16.3 Tolmar Inc Urological Cancer Drugs Sales, Revenue and Gross Margin (2017-2022)
7.16.4 Tolmar Inc Products Offered
7.16.5 Tolmar Inc Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Urological Cancer Drugs Industry Chain Analysis
8.2 Urological Cancer Drugs Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Urological Cancer Drugs Distributors
8.3 Urological Cancer Drugs Production Mode & Process
8.4 Urological Cancer Drugs Sales and Marketing
8.4.1 Urological Cancer Drugs Sales Channels
8.4.2 Urological Cancer Drugs Distributors
8.5 Urological Cancer Drugs Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
